Immunomodulator therapy in inflammatory bowel disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
6-Mercaptopurine and its prodrug counterpart, azathioprine, have proven efficacy in the induction and maintenance of remission, fistula closure, and steroid sparing in patients with Crohn’s disease. Long-term follow-up has demonstrated the safety of the purine analogues, with no increased risk of malignancy. For patients with Crohn’s disease intolerant or unresponsive to azathioprine or 6-mercaptopurine, methotrexate has emerged as an effective alternative.
In patients with severe ulcerative colitis, intravenous cyclosporine is highly efficacious in the short term, and with the addition of azathioprine or 6-mercaptopurine to oral cyclosporine, long-term remission rates of 60% to 70% can be achieved. Azathioprine or 6-mercaptopurine therapy is effective in patients with steroid-dependent or steroid-refractory colitis and is valuable in maintaining remission. Neither methotrexate nor cyclosporine has been shown to be effective for maintenance therapy in patients with ulcerative colitis.
Current data are insufficient to recommend routine use of genetic or enzymatic testing of thiopurine methyltransferase or measurements of blood 6-thioguanine metabolites to guide 6-mercaptopurine or azathioprine dosing.
- Sandborn W, Sutherland L, Pearson D, et al.: Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. In the Cochrane Library, issue 4 [online database]. Vista, CA: Update Software; 2000. http://www.update-software.com/cochrane/cochrane-frame.html A recent, comprehensive Cochrane review that critically evaluates the controlled trials of azathioprine and 6-mercaptopurine, which concludes that these drugs are effective inducing remission in patients with Crohn’s disease.
- Sandborn WJ, Tremaine WJ, Wolf DC, et al.: Lack of effect of intravenous administration on time to respond to azathioprine for steroid treated Crohn’s disease: North American Azathioprine Study Group. Gastroenterology 1999, 117:527–535. CrossRef
- Feagan BG, Ronchon J, Fedorak RN, et al., for the North American Crohn’s Disease Study Group Investigators: Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995, 332:292–297. A double-blind, placebo-controlled trial that reported methotrexate induced remission in 39% of patients with steroid-dependent, chronically active Crohn’s disease, compared with 19% for placebo. CrossRef
- Chong RY, Hanauer SB, Cohen RD: Efficacy of parenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther 2001, 15:35–44. CrossRef
- Feagan BG, McDonald JWD, Rochon J, et al., For the Canadian Crohn’s relapse prevention trial investigators. Low dose cyclosporin for the treatment of Crohn’s disease. N Engl J Med 1994, 330:1846–1851. CrossRef
- Jewell DP, Lennard-Jones JE, and the Cyclosporin Study Group of Great Britain and Ireland: Oral cyclosporin for chronic active Crohn’s disease: a multicenter controlled trial. Eur J Gastroenterol Hepatol 1994, 6:499–505. CrossRef
- Stange EF, Modigliani R, Penna AS, et al., and the European Study Group: European trial of cyclosporin in chronic active Crohn’s disease: a 12 month study. Gastroenterology 1995, 109:774–782. CrossRef
- Brynskov J, Freund L, Rasmussen SM, et al.: A placebocontrolled, double-blind, randomized controlled trial of cyclosporin therapy in active Crohn’s disease. N Engl J Med 1989, 321:845–850. CrossRef
- Egan LJ, Sandborn WJ, Tremaine WJ: Clinical outcome following treatment for refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporin. Am J Gastroenterol 1998, 93:442–448. CrossRef
- Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn’s disease. In the Cochrane Library, issue 4 [online database]. Vista, CA: Update Software; 2000. http://www.updatesoftware. com/cochrane/cochrane-frame.html A comprehensive review from the Cochrane collection that rigorously evaluates the controlled trials of azathioprine, and concludes that azathioprine is effective for maintenance of remission in patients with Crohn’s disease.
- Korelitz BI, Mirsky FJ, Fleisher MR, et al.: Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999, 94:3254–3257. CrossRef
- Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342:1627–1632. A double-blind, placebo-controlled study in patients who had methotrexate-induced remission of Crohn’s disease that demonstrated that 65% of patients are able to sustain remission using low-dosage methotrexate. CrossRef
- Lemann M, Zenjari T, Bouhnik Y, et al.: Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95:1730–1734.
- Lobo AJ, Juby LD, Rothwell J, et al.: Long-term treatment of Crohn’s disease with cyclosporin: the effect of a very low dose on the maintenance of remission. J Clin Gastroenterol 1991, 13:42–45. CrossRef
- Korelitz B, Hanauer S, Rutgeerts P, et al.: Postoperative prophylaxis with 6-MP, 5-ASA, or placebo in Crohn’s disease: a two year multicenter trial [abstract]. Gastroenterology 1998, 114:A1011. CrossRef
- Lemann M, Cuillerier E, Bouhnik Y, et al.: Azathioprine for prevention of Crohn’s recurrence after ileal or colonic resection [abstract]. Gastroenterology 1996, 110:A948.
- Korelitz BI, Adler DJ, Mendelsohn RA, et al.: Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993, 88:1198–1205.
- Korelitz BI, Present DH: Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 1985, 30:58–64. CrossRef
- Hanauer SB, Smith MB: Rapid closure of Crohn’s disease fistulas with intravenous cyclosporin A. Am J Gastroenterol 1993, 88:646–664.
- Present DH, Lichtiger S: Efficacy of cyclosporin in treatment of fistula in Crohn’s disease. Dig Dis Sci 1994, 39:374–380. CrossRef
- Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000, 6:48–57. A comprehensive article that reviews the significant side effects of chronic corticosteroid use and the expanding array of therapeutic alternative drugs for patients with Crohn’s disease or ulcerative colitis. CrossRef
- Mahadevan U, Tremaine WJ, Johnson T, et al.: Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 2000, 95:3463–3468. CrossRef
- Oren R, Arber N, Odes S, et al.: Methotrexate for chronic ulcerative colitis: a double blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110:1416–1421. CrossRef
- Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845. A randomized, double-blind, placebo-controlled trial that demonstrated an 83% success rate of intravenous cyclosporin in patients with severe ulcerative colitis. CrossRef
- Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporine in ulcerative colitis: a five year experience. Am J Gastroenterol 1999, 94:1587–1592. This report highlights the importance of giving azathioprine or 6-mercaptopurine patients who respond to cyclosporin. CrossRef
- Cohen RD, Brodsky AL, Hanauer SB: A comparison of quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999, 5:1–10. CrossRef
- George JG, Present DH, Pou R, et al.: The long term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996, 91:1711–1714.
- Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651–662.
- Colombel JF, Ferrari N, Debuysere H, et al.: Genotypic analysis of thiopurine-S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025–1030. CrossRef
- Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713. CrossRef
- Kremer JM, Alarcon GS, Lightfoot RW, et al.: Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994, 37:316–328. CrossRef
- Te HS, Schiano TS, Kuan SF, et al.: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150–3156. CrossRef
- Kornbluth A, Present DH, Lichtiger S, Hanauer SB: Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol 1997, 92:1424–1428. A practical guide for the clinician detailing the authors’ approach to prescribing and monitoring therapy with cyclosporin.
- Kozarek JM, Meller EA, Johnston A, et al.: Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporin formulation. Pharmacotherapy 1993, 13:613–617.
- Sternthal M, George J, Kornbluth A, et al.: Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease. Gastroenterology 1996, 110:A1019.
- Judge TA, Lichtenstein GR: Refractory inflammatory bowel disease. Curr Treat Opt Gastroenterol 2001, 4:267–273.
- Farrell RJ, Ang Y, Kileen P, et al.: Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk appears low. Gut 2000, 47:514–519. CrossRef
- Immunomodulator therapy in inflammatory bowel disease
Current Treatment Options in Gastroenterology
Volume 4, Issue 3 , pp 199-205
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links